Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. Getting rid of the itch

Getting rid of the itch

Stories Jun 8, 2020 4 minutes

Researchers uncover a novel approach for treating eczema.

Approximately 15-20 per cent of Canadians live with some form of atopic dermatitis (AD), also known as eczema. In a bid to find a better treatment to prevent eczema’s debilitating effects, findings by Vancouver Coastal Health Research Institute (VCHRI) researchers—recently published in the Journal of Investigative Dermatology—have identified a key enzyme that contributes to the condition. 

Eczema causes the skin’s protective barrier to break down, making it more vulnerable to foreign entities that can cause itching, inflammation, dryness and further degradation of the skin's protective barrier.

“The symptoms people often experience with eczema make them more likely to avoid going outside their homes or to work,” says VCHRI researcher and study lead, Dr. David Granville. 

Dr. David Granville is the associate director of VCHRI, a professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia (UBC) and a principal investigator with ICORD and the UBC Centre for Heart Lung Innovation.

“It is estimated that the annual cost of eczema in North America is over $5.5 billion because of how it impacts people’s health and well-being.”

Dr. Chris Turner, the study’s first author and a postdoctoral fellow in Granville’s laboratory, found that the Granzyme B enzyme is positively correlated with itchiness and disease severity in eczema. Granzyme B also weakens skin by cleaving through the proteins holding cells together. 

“Between cells in our skin are proteins that anchor them tightly together,” says Granville. “In some inflammatory diseases, such as eczema, Granzyme B is secreted by cells and eats away at those proteins, causing these bonds to weaken and the skin to become further inflamed and itchy.”
 

Breaking down the wall. Granzyme B cleaves proteins that are vital to maintaining a protective skin barrier. When these are lost, pathogens and other substances may cross the barrier and trigger inflammation.

Researchers found that by knocking out Granzyme B with genetic modification, or inhibiting it with a topical gel, they could prevent it from damaging the skin barrier and significantly reduce the severity of AD.

“Previous work had suggested that Granzyme B levels correlate with the degree of itchiness and disease severity in patients with atopic dermatitis; however, there was no evidence that this enzyme played any causative role,” says Granville. 

“Our study provides evidence that topical drugs targeting Granzyme B could be used to treat dermatitis in patients with eczema and other forms of dermatitis.”  

Researchers aim to quash the root cause of eczema symptoms

AD affects between 10-15 per cent of Canadian children under age five. Of those, around 40 per cent will experience symptoms of the disease for the rest of their lives1.

It is also associated with an increased risk of developing a host of other inflammatory conditions, including food allergies, asthma and allergic rhinitis, notes Turner.

"Atopic dermatitis is the leading non-fatal health burden attributable to skin diseases.”

AD typically follows an itch-scratch cycle in which itchiness is followed by scratching and more itchiness. This cycle usually occurs during flare-ups, which can appear anytime, and sometimes weeks, months or years apart.

Dr. Christopher Turner is a postdoctoral fellow with the International Collaboration on Repair Discoveries (ICORD) and Canadian Institutes of Health Research (CIHR).

Corticosteroid creams are a common treatment for individuals with AD who experience more severe itching and rashes. However, these can thin the skin when used over a prolonged period of time, which can make skin more prone to damage and infection.

A gel or cream that stops or limits Granzyme B, thereby reducing the severity of AD, could be a safer and more effective long-term treatment, says Turner. 

“A gel or cream that blocks Granzyme B could have fewer if any side-effects and circumvent the itch-scratch cycle, making flare-ups less pronounced.”

While a commercially available treatment is still a ways away, Turner and Granville see great promise in this line of research, and are pursuing further clinical trials into Granzyme B and Granzyme B inhibitors. 
 

1 Canadian Skill Patient Alliance - Atopic Dermatitis (Eczema)

Researchers

David Granville

Related Articles

Facing the facts: Suture materials and scar prominence post-surgery

Ask an expert: How can I reduce my risk of developing skin cancer?

Ask an expert: Do I need to wear sunscreen in the winter?

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Related Research Centres/Programs

International Collaboration on Repair Discoveries

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Celebrating the life and distinguished career of Dr. Marcel Dvorak

May 14, 2025
Type
Stories

More equitable representation needed in Parkinson’s research

May 9, 2025 parkinsons, patient engagement, women
Type
Stories

Gamified stroke recovery improves arm function

May 8, 2025 stroke, rehabilitation
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy